Oslo, Norway, June 2, 2022 - Nykode Therapeutics ASA (Euronext Growth (Oslo):
NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and
development of vaccines and novel immunotherapies, today announced that its
conversion to a public limited liability company has been registered. 

Reference is made to the stock exchange announcement made on May 12, 2022 by
Nykode Therapeutics ASA regarding the annual general meeting held the same date.
The resolutions made by the general meeting, including, inter alia, the
conversion of the company into a public limited liability company, change of
company name and, consequently, necessary amendments to the articles of
association, have now been registered with the Norwegian Register of Business
Enterprises. The new name of the company is Nykode Therapeutics ASA.


Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen specific immune responses
and eliciting efficacious clinical responses. 

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive interim efficacy and safety results from its Phase II
trial for the treatment of cervical cancer